Prognostic Significance of LncRNA GHET1 Expression in Various Cancers: a Systematic Review and Meta-analysis

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2019 Jun 23

PMID 31227613

Citations 3

Authors

Jing Ye

Haiyan Sun

Zhengquan Feng

Qiqin Zhang

Yongliang Xia

Yunxi Ji

Qiqing Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Dysregulated expression of long non-coding RNA gastric carcinoma high expressed transcript 1 (lncRNA GHET1) has been observed in several cancers, however, definite conclusion on the prognostic value of lncRNA GHET1 expression in human cancers has not been determined. The aim of this meta-analysis was to evaluate the prognostic significance of lncRNA GHET1 expression in cancers.

Methods: PubMed, Web of Science and Embase were comprehensively searched for relevant studies. Meta-analyses of overall survival (OS) and clinicopathological features were conducted.

Results: Ten studies were finally analyzed in the present study. High lncRNA GHET1 expression was associated with shorter OS than low lncRNA GHET1 expression in cancers (hazard ratio (HR) = 2.59, 95% CI = 1.93-3.47, P<0.01). Online cross-validation using The Cancer Genome Atlas (TCGA) data observed similar results (HR = 1.10, P<0.05). When compared with low lncRNA GHET1 expression, high lncRNA GHET1 expression was related to larger tumor size (P<0.01), worse differentiation (P<0.01), earlier distant metastasis (P=0.02), earlier lymph node metastasis (P<0.01) and more advanced clinical stage (P<0.01).

Conclusion: High lncRNA GHET1 expression is associated with worse cancer prognosis and can serve as a promising prognostic factor of human cancers.

Citing Articles

HOXA-AS2 may be a potential prognostic biomarker in human cancers: A meta-analysis and bioinformatics analysis.

Zhang F, Zhang G, Zhang H, Pu X, Chi F, Zhang D Front Genet. 2022; 13:944278.

PMID: 36437956 PMC: 9686854. DOI: 10.3389/fgene.2022.944278.

Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.

Zhang C, Ren X, Zhang W, He L, Qi L, Chen R Bioengineered. 2020; 11(1):1112-1123.

PMID: 33124951 PMC: 8291808. DOI: 10.1080/21655979.2020.1831361.

Serum interleukin-6 level is correlated with the disease activity of systemic lupus erythematosus: a meta-analysis.

Ding J, Su S, You T, Xia T, Lin X, Chen Z Clinics (Sao Paulo). 2020; 75:e1801.

PMID: 33084768 PMC: 7536892. DOI: 10.6061/clinics/2020/e1801.

References

Jandura A, Krause H . The New RNA World: Growing Evidence for Long Noncoding RNA Functionality. Trends Genet. 2017; 33(10):665-676. DOI: 10.1016/j.tig.2017.08.002. View

Liu X, Ming X, Jing W, Luo P, Li N, Zhu M . Long non-coding RNA XIST predicts worse prognosis in digestive system tumors: a systemic review and meta-analysis. Biosci Rep. 2018; 38(3). PMC: 6013696. DOI: 10.1042/BSR20180169. View

Miller K, Siegel R, Lin C, Mariotto A, Kramer J, Rowland J . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-89. DOI: 10.3322/caac.21349. View

Zhou Y, Cheng S, Chen S, Zhao Y . Prognostic and clinicopathological value of SIRT3 expression in various cancers: a systematic review and meta-analysis. Onco Targets Ther. 2018; 11:2157-2167. PMC: 5907887. DOI: 10.2147/OTT.S157836. View

Guan Z, Cao Y, Li Y, Tong W, Zhuo A . Knockdown of lncRNA GHET1 suppresses cell proliferation, invasion and LATS1/YAP pathway in non small cell lung cancer. Cancer Biomark. 2017; 21(3):557-563. DOI: 10.3233/CBM-170431. View

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

Yang F, Xue X, Zheng L, Bi J, Zhou Y, Zhi K . Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability. FEBS J. 2014; 281(3):802-13. DOI: 10.1111/febs.12625. View

Yu L, Chen S, Bao H, Zhang W, Liao M, Liang Q . The role of lncRNA CASC2 on prognosis of malignant tumors: a meta-analysis and bioinformatics. Onco Targets Ther. 2018; 11:4355-4365. PMC: 6065597. DOI: 10.2147/OTT.S166132. View

Zhou H, Zhu H, Wu X, Chen X, Qiao Z, Ling X . Expression and clinical significance of long-non-coding RNA GHET1 in pancreatic cancer. Eur Rev Med Pharmacol Sci. 2017; 21(22):5081-5088. DOI: 10.26355/eurrev_201711_13822. View

10.

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

11.

Shen Q, Wang H, Xu S . LncRNA GHET1 predicts a poor prognosis of the patients with non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2018; 22(8):2328-2333. DOI: 10.26355/eurrev_201804_14823. View

12.

Zhou Y, Cheng S, Fathy A, Qian H, Zhao Y . Prognostic value of platelet-to-lymphocyte ratio in pancreatic cancer: a comprehensive meta-analysis of 17 cohort studies. Onco Targets Ther. 2018; 11:1899-1908. PMC: 5896656. DOI: 10.2147/OTT.S154162. View

13.

Liu H, Wu Y . Long non-coding RNA gastric carcinoma highly expressed transcript 1 promotes cell proliferation and invasion in human head and neck cancer. Oncol Lett. 2018; 15(5):6941-6946. PMC: 5920369. DOI: 10.3892/ol.2018.8185. View

14.

Espinosa J . On the Origin of lncRNAs: Missing Link Found. Trends Genet. 2017; 33(10):660-662. PMC: 5610073. DOI: 10.1016/j.tig.2017.07.005. View

15.

Liu H, Zhen Q, Fan Y . LncRNA GHET1 promotes esophageal squamous cell carcinoma cells proliferation and invasion via induction of EMT. Int J Biol Markers. 2017; 32(4):e403-e408. DOI: 10.5301/ijbm.5000304. View

16.

Zhang T, Wu D, Deng S, Han R, Liu T, Li J . Integrated Analysis Reveals That Long Non-Coding RNA TUBA4B Can Be Used as a Prognostic Biomarker in Various Cancers. Cell Physiol Biochem. 2018; 49(2):530-544. DOI: 10.1159/000492991. View

17.

Slaby O, Laga R, Sedlacek O . Therapeutic targeting of non-coding RNAs in cancer. Biochem J. 2017; 474(24):4219-4251. DOI: 10.1042/BCJ20170079. View

18.

Xia Y, Yan Z, Wan Y, Wei S, Bi Y, Zhao J . Knockdown of long noncoding RNA GHET1 inhibits cell‑cycle progression and invasion of gastric cancer cells. Mol Med Rep. 2018; 18(3):3375-3381. PMC: 6102745. DOI: 10.3892/mmr.2018.9332. View

19.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

20.

Ni W, Luo L, Zuo P, Li R, Xu X, Wen F . lncRNA GHET1 down-regulation suppresses the cell activities of glioma. Cancer Biomark. 2018; 23(1):9-22. DOI: 10.3233/CBM-171002. View